MARKET

STVN

STVN

Stevanato Group S P A
NYSE
27.22
+0.68
+2.56%
After Hours: 27.22 0 0.00% 16:00 04/23 EDT
OPEN
26.61
PREV CLOSE
26.54
HIGH
27.88
LOW
26.58
VOLUME
233.11K
TURNOVER
0
52 WEEK HIGH
36.30
52 WEEK LOW
23.00
MARKET CAP
7.42B
P/E (TTM)
44.84
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at STVN last week (0415-0419)?
Weekly Report · 1d ago
Weekly Report: what happened at STVN last week (0408-0412)?
Weekly Report · 04/15 09:25
Weekly Report: what happened at STVN last week (0401-0405)?
Weekly Report · 04/08 09:26
Stevanato names Ugo Gay as its new COO
Stevanato names Ugo Gay as its new COO. Gay has nearly three decades of experience in industry, business management, supply chain and operations. Stevanato Group S.p.A. (STVN) The company has appointed Gay as the new CEO.
Seeking Alpha · 04/04 12:24
Stevanato Group Appoints Ugo Gay As Chief Operations Officer
Strengthening corporate leadership aims to drive operational efficiencies and standardization of global processes. Stevanato Group S.p.A. Announced the appointment of Ugo Gay as its new Chief Operations Officer (COO) Ugo gay brings nearly three decades of experience in industry, business management, supply chain, and operations to the company. The company is a leading provider of drug containment, drug delivery, and diagnostic solutions.
Benzinga · 04/04 12:14
Weekly Report: what happened at STVN last week (0325-0329)?
Weekly Report · 04/01 09:26
International Companies Drive Diabesity Innovation
Diabetes and obesity markets are large and growing, with an estimated total long-term addressable market of $100 billion in the US alone. Denmark's Novo Nordisk and US-based Eli Lilly are leading pharmaceutical companies in the development of GLP-1-based treatments for diabetes and obesity. There is potential for global market expansion as millions of people are obese or at risk for diabetes but not receiving treatment.
Seeking Alpha · 03/29 13:59
Stevanato Group Completes Major Share Offering
Stevanato Group S.p.A., a major player in pharmaceutical and life sciences solutions, has successfully closed an upsized public offering. The company raised $379.7 million through the sale of 14,605,000 ordinary shares. STVN aims to utilize the proceeds for general corporate purposes.
TipRanks · 03/27 10:59
More
About STVN
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.

Webull offers Stevanato Group SpA stock information, including NYSE: STVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STVN stock methods without spending real money on the virtual paper trading platform.